Daniel T O'connor

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11896624/publications.pdf

Version: 2024-02-01

197 papers	10,076 citations	30070 54 h-index	45317 90 g-index
200 all docs	200 docs citations	200 times ranked	8596 citing authors

#	Article	IF	Citations
1	The Chromograninâ€“Secretogranin Family. New England Journal of Medicine, 2003, 348, 1134-1149.	27.0	770
2	Secretion of Chromogranin A by Peptide-Producing Endocrine Neoplasms. New England Journal of Medicine, 1986, 314, 1145-1151.	27.0	464
3	Assessment of Plasma C-Reactive Protein as a Biomarker of Posttraumatic Stress Disorder Risk. JAMA Psychiatry, 2014, 71, 423.	11.0	290
4	Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. Journal of Clinical Investigation, 2005, 115, 1942-1952.	8.2	277
5	Chromogranin A: Immunohistology reveals its universal occurrence in normal polypeptide hormone producing endocrine glands. Life Sciences, 1983, 33, 1657-1663.	4.3	237
6	Whole-Genome Analysis of Sporadic Amyotrophic Lateral Sclerosis. New England Journal of Medicine, 2007, 357, 775-788.	27.0	234
7	Radioimmunoassay of Chromogranin a in Plasma as a Measure of Exocytotic Sympathoadrenal Activity in Normal Subjects and Patients with Pheochromocytoma. New England Journal of Medicine, 1984, 311, 764-770.	27.0	217
8	Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum. Regulatory Peptides, 1983, 6, 263-280.	1.9	202
9	Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension.. Journal of Hypertension, 2002, 20, 1335-1345.	0.5	182
10	Biomarkers of PTSD: Neuropeptides and immune signaling. Neuropharmacology, 2012, 62, 663-673.	4.1	162
11	Tissue Plasminogen Activator (t-PA) Is Targeted to the Regulated Secretory Pathway. Journal of Biological Chemistry, 1997, 272, 1976-1982.	3.4	148
12	Genomic predictors of combat stress vulnerability and resilience in U.S. Marines: A genome-wide association study across multiple ancestries implicates PRTFDC1 as a potential PTSD gene. Psychoneuroendocrinology, 2015, 51, 459-471.	2.7	147
13	iPSCORE: A Resource of 222 iPSC Lines Enabling Functional Characterization of Genetic Variation across a Variety of Cell Types. Stem Cell Reports, 2017, 8, 1086-1100.	4.8	147
14	Dopamine Î²-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Human Genetics, 1998, 102, 533-540.	3.8	127
15	Chromogranin A in uremia: Progressive retention of immunoreactive fragments. Kidney International, 1990, 37, 955-964.	5.2	125
16	The Crucial Role of Chromogranins in Storage and Exocytosis Revealed Using Chromaffin Cells from Chromogranin A Null Mouse. Journal of Neuroscience, 2008, 28, 3350-3358.	3.6	120
17	Population-Based Sample Reveals Geneâ€“Gender Interactions in Blood Pressure in White Americans. Hypertension, 2007, 49, 96-106.	2.7	107
18	Catecholamine Releaseâ€“Inhibitory Peptide Catestatin (Chromogranin A 352â€“372). Circulation, 2007, 115, 2271-2281.	1.6	105

#	Article	IF	Citations
19	Both Rare and Common Polymorphisms Contribute Functional Variation at CHGA, a Regulator of Catecholamine Physiology. American Journal of Human Genetics, 2004, 74, 197-207.	6.2	104
20	The Neuroendocrine Peptide Catestatin Is a Cutaneous Antimicrobial and Induced in the Skin after Injury. Journal of Investigative Dermatology, 2008, 128, 1525-1534.	0.7	103
21	Catestatin: A multifunctional peptide from chromogranin A. Regulatory Peptides, 2010, 162, 33-43.	1.9	102
22	Genetic loci associated with heart rate variability and their effects on cardiac disease risk. Nature Communications, 2017, 8, 15805.	12.8	95
23	Desensitization of Catecholamine Release. Journal of Biological Chemistry, 1999, 274, 2920-2928.	3.4	94
24	Tyrosine Hydroxylase, the Rate-Limiting Enzyme in Catecholamine Biosynthesis. Circulation, 2007, 116, 993-1006.	1.6	89
25	C-reactive protein, an â€˜intermediate phenotypeâ€™ for inflammation: human twin studies reveal heritability, association with blood pressure and the metabolic syndrome, and the influence of common polymorphism at catecholaminergic/Î²-adrenergic pathway loci. Journal of Hypertension, 2007, 25, 329-343.	0.5	88
26	A Novel Pathway of Insulin Sensitivity in Chromogranin A Null Mice. Journal of Biological Chemistry, 2009, 284, 28498-28509.	3.4	87
27	Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk. Journal of Clinical Investigation, 2007, 117, 2658-2671.	8.2	87
28	The Catecholamine Release-Inhibitory â€œCatestatinâ€•Fragment of Chromogranin A: Naturally Occurring Human Variants with Different Potencies for Multiple Chromaffin Cell Nicotinic Cholinergic Responses. Molecular Pharmacology, 2004, 66, 1180-1191.	2.3	86
29	Functional allelic heterogeneity and pleiotropy of a repeat polymorphism in tyrosine hydroxylase: prediction of catecholamines and response to stress in twins. Physiological Genomics, 2004, 19, 277-291.	2.3	80
30	Heart Rate Variability Characteristics in a Large Group of Active-Duty Marines and Relationship to Posttraumatic Stress. Psychosomatic Medicine, 2014, 76, 292-301.	2.0	80
31	Chromogranin A in familial pheochromocytoma: Diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. American Journal of Medicine, 1990, 88, 607-613.	1.5	79
32	Pancreastatin: Multiple Actions on Human Intermediary Metabolismin Vivo, Variation in Disease, and Naturally Occurring Functional Genetic Polymorphism. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5414-5425.	3.6	79
33	Heritability and Genome-Wide Linkage in US and Australian Twins Identify Novel Genomic Regions Controlling Chromogranin A. Circulation, 2008, 118, 247-257.	1.6	79
34	Direct Vasoactive Effects of the Chromogranin A (CHGA) Peptide Catestatin in HumansIn Vivo. Clinical and Experimental Hypertension, 2010, 32, 278-287.	1.3	79
35	Catecholamine Secretory Vesicle Stimulus-Transcription Coupling in Vivo. Journal of Biological Chemistry, 2003, 278, 32058-32067.	3.4	73
36	Identification of a novel sorting determinant for the regulated pathway in the secretory protein chromogranin A. Journal of Cell Science, 2002, 115, 4827-4841.	2.0	72

#	Article	IF	Citations
37	Role of H+-ATPase-mediated Acidification in Sorting and Release of the Regulated Secretory Protein Chromogranin A. Journal of Biological Chemistry, 2005, 280, 3885-3897.	3.4	71
38	Rho Kinase Polymorphism Influences Blood Pressure and Systemic Vascular Resistance in Human Twins. Hypertension, 2006, 47, 937-947.	2.7	70
39	Neuroendocrine Nicotinic Receptor Activation Increases Susceptibility to Bacterial Infections by Suppressing Antimicrobial Peptide Production. Cell Host and Microbe, 2010, 7, 277-289.	11.0	69
40	Proteolytic Cleavage of Chromogranin A (CgA) by Plasmin. Journal of Biological Chemistry, 2001, 276, 25022-25029.	3.4	68
41	Polymorphisms and Haplotypes of the Regulator of G Protein Signaling-2 Gene in Normotensives and Hypertensives. Hypertension, 2006, 47, 415-420.	2.7	68
42	Formation of the Catecholamine Release-inhibitory Peptide Catestatin from Chromogranin A. Journal of Biological Chemistry, 2000, 275, 22905-22915.	3.4	67
43	Cathepsin L Colocalizes with Chromogranin A in Chromaffin Vesicles to Generate Active Peptides. Endocrinology, 2009, 150, 3547-3557.	2.8	67
44	Predictors of Risk and Resilience for Posttraumatic Stress Disorder Among Ground Combat Marines: Methods of the Marine Resiliency Study. Preventing Chronic Disease, 2012, 9, E97.	3.4	66
45	Common Genetic Mechanisms of Blood Pressure Elevation in Two Independent Rodent Models of Human Essential Hypertension. American Journal of Hypertension, 2005, 18, 633-652.	2.0	65
46	Sp1 and CREB Mediate Gastrin-dependent Regulation of Chromogranin A Promoter Activity in Gastric Carcinoma Cells. Journal of Biological Chemistry, 1998, 273, 34000-34007.	3.4	64
47	Catestatin (Chromogranin A352â€“372) and Novel Effects on Mobilization of Fat from Adipose Tissue through Regulation of Adrenergic and Leptin Signaling. Journal of Biological Chemistry, 2012, 287, 23141-23151.	3.4	63
48	Catecholamine storage vesicle protein expression in genetic hypertension. Blood Pressure, 1999, 8, 285-295.	1.5	61
49	Global Disturbances in Autonomic Function Yield Cardiovascular Instability and Hypertension in the Chromogranin A Null Mouse. Endocrinology, 2009, 150, 5027-5035.	2.8	60
50	Chromogranin a correlates with norepinephrine release rate. Life Sciences, 1992, 51, 519-525.	4.3	59
51	Pancreastatin-Dependent Inflammatory Signaling Mediates Obesity-Induced Insulin Resistance. Diabetes, 2015, 64, 104-116.	0.6	59
52	Chromogranin A Polymorphisms Are Associated With Hypertensive Renal Disease. Journal of the American Society of Nephrology: JASN, 2008, 19, 600-614.	6.1	58
53	Sympathoâ€adrenal secretion in humans: factors governing catecholamine and storage vesicle peptide coâ€release *. Autonomic and Autacoid Pharmacology, 1994, 14, 187-200.	0.6	57
54	Modulatory Mechanism of the Endogenous Peptide Catestatin on Neuronal Nicotinic Acetylcholine Receptors and Exocytosis. Journal of Neuroscience, 2002, 22, 377-388.	3.6	56

#	Article	IF	Citations
55	Butyrylcholinesterase: Association with the Metabolic Syndrome and Identification of 2 Gene Loci Affecting Activity. Clinical Chemistry, 2006, 52, 1014-1020.	3.2	56
56	Hereditary Determinants of Human Hypertension. Hypertension, 2008, 51, 1456-1464.	2.7	53
57	Genetic Covariance Between Î³-Glutamyl Transpeptidase and Fatty Liver Risk Factors: Role of Î²2-Adrenergic Receptor Genetic Variation in Twins. Gastroenterology, 2010, 139, 836-845.e1.	1.3	53
58	Stimulus-transcription Coupling in Pheochromocytoma Cells. Journal of Biological Chemistry, 1996, 271, 28382-28390.	3.4	52
59	A Dynamic Pool of Calcium in Catecholamine Storage Vesicles. Journal of Biological Chemistry, 2004, 279, 51107-51121.	3.4	51
60	Secretory Granule Biogenesis in Sympathoadrenal Cells. Journal of Biological Chemistry, 2006, 281, 38038-38051.	3.4	51
61	A Proposed Role for Chromogranin A as a Glucocorticoid-Responsive Autocrine Inhibitor of Proopiomelanocortin Secretion*. Endocrinology, 1991, 128, 1345-1351.	2.8	50
62	Renal Albumin Excretion. Hypertension, 2007, 49, 1015-1031.	2.7	50
63	Proteolytic Cleavage of Human Chromogranin A Containing Naturally Occurring Catestatin Variants: Differential Processing at Catestatin Region by Plasmin. Endocrinology, 2008, 149, 749-757.	2.8	50
64	Human dopamine beta-hydroxylase (DBH) regulatory polymorphism that influences enzymatic activity, autonomic function, and blood pressure. Journal of Hypertension, 2010, 28, 76-86.	0.5	48
65	Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga364â€“384). Cell and Tissue Research, 2010, 342, 353-361.	2.9	48
66	Proteomics of Dense Core Secretory Vesicles Reveal Distinct Protein Categories for Secretion of Neuroeffectors for Cellâˆ’Cell Communication. Journal of Proteome Research, 2010, 9, 5002-5024.	3.7	48
67	Plasma Norepinephrine Kinetics, Dopamine-Î²-Hydroxylase, and Chromogranin-A, in Hypothyroid Patients before and following Replacement Therapy*. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 277-281.	3.6	46
68	MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: functional and therapeutic implications for gene expression and the pathogenesis of hypertension. Human Molecular Genetics, 2013, 22, 3624-3640.	2.9	46
69	Naturally Occurring Human Genetic Variation in the 3â€²-Untranslated Region of the Secretory Protein Chromogranin A Is Associated With Autonomic Blood Pressure Regulation and Hypertension in a Sex-Dependent Fashion. Journal of the American College of Cardiology, 2008, 52, 1468-1481.	2.8	44
70	Heritability of Biomarkers of Oxidized Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1704-1711.	2.4	44
71	Arterial Compliance by Cuff Sphygmomanometer. Hypertension, 1996, 28, 599-603.	2.7	44
72	Norepinephrine clearance, chromogranin A and dopamine Î² hydroxylase in renal failure. Kidney International, 1990, 37, 1357-1362.	5.2	43

#	Article	IF	Citations
73	Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. Journal of Hypertension, 2007, 25, 2082-2092.	0.5	43
74	Interactive Effects of Common Î² 2 -Adrenoceptor Haplotypes and Age on Susceptibility to Hypertension and Receptor Function. Hypertension, 2005, 46, 301-307.	2.7	42
75	Role of Reactive Oxygen Species in Hyperadrenergic Hypertension. Circulation: Cardiovascular Genetics, 2010, 3, 414-425.	5.1	42
76	Chromogranin A as Tumor Marker in Medullary Thyroid Carcinoma. Thyroid, 1992, 2, 5-10.	4.5	41
77	Mechanism of action of chromogranin A on catecholamine release: molecular modeling of the catestatin region reveals a Î²-strand/loop/Î²-strand structure secured by hydrophobic interactions and predictive of activity. Regulatory Peptides, 1998, 77, 43-53.	1.9	39
78	Human sympathetic activation by ?2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450?mediated drug metabolism*1. Clinical Pharmacology and Therapeutics, 2004, 76, 139-153.	4.7	38
79	Pro-hormone Secretogranin II Regulates Dense Core Secretory Granule Biogenesis in Catecholaminergic Cells. Journal of Biological Chemistry, 2010, 285, 10030-10043.	3.4	38
80	Neuroendocrine Transcriptome in Genetic Hypertension. Hypertension, 2004, 43, 1301-1311.	2.7	37
81	The amino terminal sequences of bovine and human chromogranin A and secretory protein i are identical. Biochemical and Biophysical Research Communications, 1985, 127, 380-383.	2.1	36
82	Autonomic and Hemodynamic Origins of Pre-Hypertension. Journal of the American College of Cardiology, 2012, 59, 2206-2216.	2.8	36
83	Genetic Implication of a Novel Thiamine Transporter in Human Hypertension. Journal of the American College of Cardiology, 2014, 63, 1542-1555.	2.8	36
84	The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters. Journal of Hypertension, 2006, 24, 895-904.	0.5	35
85	Pancreastatin-like immunoreactivity in human carcinoid disease. Regulatory Peptides, 1991, 33, 55-70.	1.9	34
86	Chromogranin A: localization and stoichiometry in large dense core catecholamine storage vesicles from sympathetic nerve. Brain Research, 1991, 567, 188-196.	2.2	34
87	Biogenesis of the Secretory Granule:â€‰ Chromogranin A Coiled-Coil Structure Results in Unusual Physical Properties and Suggests a Mechanism for Granule Core Condensation. Biochemistry, 2007, 46, 10999-11012.	2.5	34
88	Chromogranin A and the Autonomic System: Decomposition of Heart Rate Variability and Rescue by Its Catestatin Fragment. Endocrinology, 2010, 151, 2760-2768.	2.8	34
89	Primary Sequence Characterization of Catestatin Intermediates and Peptides Defines Proteolytic Cleavage Sites Utilized for Converting Chromogranin A into Active Catestatin Secreted from Neuroendocrine Chromaffin Cellsâ€. Biochemistry, 2003, 42, 6938-6946.	2.5	33
90	Primary culture of bovine chromaffin cells. Nature Protocols, 2007, 2, 1248-1253.	12.0	32

#	Article	IF	Citations
91	Vesicular Monoamine Transport Inhibitors. Hypertension, 1996, 28, 414-420.	2.7	32
92	Renal hemodynamic changes during long-term antihypertensive therapy. Clinical Pharmacology and Therapeutics, 1981, 29, 310-317.	4.7	31
93	Catecholamine storage vesicles and the metabolic syndrome: the role of the chromogranin A fragment pancreastatin. Diabetes, Obesity and Metabolism, 2006, 8, 621-633.	4.4	31
94	Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses. Journal of Hypertension, 2010, 28, 817-825.	0.5	31
95	A Common Genetic Variant in the 3â€²-UTR of Vacuolar H⁺-ATPaseATP6V0A1Creates a Micro-RNA Motif to Alter Chromogranin A Processing and Hypertension Risk. Circulation: Cardiovascular Genetics, 2011, 4, 381-389.	5.1	31
96	Novel Peptide Isomer Strategy for Stable Inhibition of Catecholamine Release. Hypertension, 2012, 60, 1552-1559.	2.7	31
97	Nicotinic Acetylcholine Receptors in Glucose Homeostasis: The Acute Hyperglycemic and Chronic Insulin-Sensitive Effects of Nicotine Suggest Dual Opposing Roles of the Receptors in Male Mice. Endocrinology, 2014, 155, 3793-3805.	2.8	31
98	Dispersion of Chromogranin/Secretogranin Secretory Protein Family Loci in Mammalian Genomes. Genomics, 1996, 33, 135-139.	2.9	30
99	Assessment of multiple displacement amplification for polymorphism discovery and haplotype determination at a highly polymorphic locus,MC1R. Human Mutation, 2005, 26, 145-152.	2.5	29
100	An ancestral variant of Secretogranin II confers regulation by PHOX2 transcription factors and association with hypertension. Human Molecular Genetics, 2007, 16, 1752-1764.	2.9	29
101	Mass Spectrometry-Based Neuropeptidomics of Secretory Vesicles from Human Adrenal Medullary Pheochromocytoma Reveals Novel Peptide Products of Prohormone Processing. Journal of Proteome Research, 2010, 9, 5065-5075.	3.7	29
102	Neuropeptide Y1Receptor NPY1R. Journal of the American College of Cardiology, 2009, 54, 944-954.	2.8	28
103	Human Tyrosine Hydroxylase Natural Genetic Variation. Circulation: Cardiovascular Genetics, 2010, 3, 187-198.	5.1	28
104	Conformational preferences and activities of peptides from the catecholamine release-inhibitory (catestatin) region of chromogranin A. Regulatory Peptides, 2004, 118, 75-87.	1.9	27
105	Genetic Variation at the Human Î± 2B -Adrenergic Receptor Locus. Hypertension, 2005, 45, 1207-1213.	2.7	27
106	Molecular basis of neuroendocrine cell type-specific expression of the chromograninâ€ƒB gene: crucial role of the transcription factors CREB, AP-2, Egr-1 and Sp1. Journal of Neurochemistry, 2006, 99, 119-133.	3.9	27
107	Characterization of cerebrospinal fluid (CSF) and plasma NPY levels in normal volunteers over a 24-h timeframe. Psychoneuroendocrinology, 2013, 38, 2378-2382.	2.7	27
108	Secretin Activation of Chromogranin A Gene Transcription. Journal of Biological Chemistry, 2003, 278, 19986-19994.	3.4	26

#	Article	IF	Citations
109	Autonomic Function in Hypertension. Circulation: Cardiovascular Genetics, 2009, 2, 46-56.	5.1	26
110	Genome-wide case/control studies in hypertension: only the â€˜tip of the icebergâ€™. Journal of Hypertension, 2010, 28, 1115-1123.	0.5	26
111	Human response to Î±-adrenergic agonist stimulation studied in an isolated vascular bed in vivo: Biphasic influence of dose, age, gender, and receptor genotype. Clinical Pharmacology and Therapeutics, 2005, 77, 388-403.	4.7	25
112	The catecholamine biosynthetic enzyme dopamine Î²-hydroxylase (DBH): first genome-wide search positions trait-determining variants acting additively in the proximal promoter. Human Molecular Genetics, 2014, 23, 6375-6384.	2.9	25
113	Dopamine-?-Hydroxylase: Structural Comparisons of Membrane-Bound Versus Soluble Forms from Adrenal Medulla and Pheochromocytoma. Journal of Neurochemistry, 1985, 44, 411-420.	3.9	24
114	Chromogranin A Regulates Renal Function by Triggering Weibelâ€“Palade Body Exocytosis. Journal of the American Society of Nephrology: JASN, 2009, 20, 1623-1632.	6.1	24
115	Human catestatin peptides differentially regulate infarct size in the ischemicâ€“reperfused rat heart. Regulatory Peptides, 2010, 165, 63-70.	1.9	24
116	Preserved Renal Perfusion During Treatment of Essential Hypertension with the Beta Blocker Nadolol. Journal of Clinical Pharmacology, 1982, 22, 187-195.	2.0	23
117	Chromogranin B: isolation from pheochromocytoma, N-terminal sequence, tissue distribution and secretory vesicle processing. Regulatory Peptides, 1991, 33, 223-235.	1.9	23
118	Neuropeptidomic Components Generated by Proteomic Functions in Secretory Vesicles for Cellâ€“Cell Communication. AAPS Journal, 2010, 12, 635-645.	4.4	23
119	How Sensitive and Specific Is Measurement of Plasma Chromogranin A for the Diagnosis of Neuroendocrine Neoplasia?a. Annals of the New York Academy of Sciences, 1987, 493, 379-386.	3.8	22
120	Plasma Chromogranin-A in Primary Hyperparathyroidism*. Journal of Clinical Endocrinology and Metabolism, 1989, 69, 950-955.	3.6	22
121	Hormone Storage Vesicle Proteins.. Annals of the New York Academy of Sciences, 1994, 733, 36-45.	3.8	22
122	Naturally Occurring Variations in the Human Cholinesterase Genes: Heritability and Association with Cardiovascular and Metabolic Traits. Journal of Pharmacology and Experimental Therapeutics, 2011, 338, 125-133.	2.5	22
123	Early Inflammatory and Metabolic Changes in Association With AGTR1 Polymorphisms in Prehypertensive Subjects. American Journal of Hypertension, 2011, 24, 225-233.	2.0	22
124	Neuropeptide Y (NPY). Journal of the American College of Cardiology, 2012, 60, 1678-1689.	2.8	22
125	The trans-Golgi Proteins SCLIP and SCG10 Interact with Chromogranin A To Regulate Neuroendocrine Secretion. Biochemistry, 2008, 47, 7167-7178.	2.5	21
126	Human Dopamine Â-Hydroxylase Promoter Variant Alters Transcription in Chromaffin Cells, Enzyme Secretion, and Blood Pressure. American Journal of Hypertension, 2011, 24, 24-32.	2.0	21

#	Article	IF	Citations
127	Discovery of a Novel Target for the Dysglycemic Chromogranin A Fragment Pancreastatin: Interaction with the Chaperone GRP78 to Influence Metabolism. PLoS ONE, 2014, 9, e84132.	2.5	21
128	Malignant and Benign Pheochromocytoma. Annals of the New York Academy of Sciences, 2002, 971, 530-532.	3.8	20
129	Early Phenotypic Changes in Hypertension. Hypertension, 2006, 47, 331-333.	2.7	20
130	Common Functional Genetic Variants in Catecholamine Storage Vesicle Protein Promoter Motifs Interact to Trigger Systemic Hypertension. Journal of the American College of Cardiology, 2010, 55, 1463-1475.	2.8	20
131	Skin pretreatment and the use of transdermal clonidine. American Journal of Medicine, 1991, 91, S42-S49.	1.5	19
132	Studies of the Dysglycemic Peptide, Pancreastatin, Using a Human Forearm Model. Annals of the New York Academy of Sciences, 2002, 971, 528-529.	3.8	19
133	Phenylethanolamine N-Methyltransferase Gene Polymorphisms and Adverse Outcomes in Acute Kidney Injury. Nephron Clinical Practice, 2010, 114, c253-c259.	2.3	19
134	Molecular Cloning, Structure, and Expression of Dopamine-??Hydroxylase from Bovine Adrenal Medulla. Journal of Neurochemistry, 1990, 55, 97-105.	3.9	18
135	Assignment of the Chromogranin A (Chga) Locus to Homologous Regions on Mouse Chromosome 12 and Rat Chromosome 6. Genomics, 1993, 17, 252-255.	2.9	18
136	Pleiotropic effects of novel trans-acting loci influencing human sympathochromaffin secretion. Physiological Genomics, 2006, 25, 470-479.	2.3	18
137	Heredity of Endothelin Secretion. Circulation, 2007, 115, 2282-2291.	1.6	18
138	Adrenergic Polymorphism and the Human Stress Response. Annals of the New York Academy of Sciences, 2008, 1148, 282-296.	3.8	18
139	Genetic Variation Within Adrenergic Pathways Determines In Vivo Effects of Presynaptic Stimulation in Humans. Circulation, 2008, 117, 517-525.	1.6	18
140	CSF chromogranin A-like immunoreactivity in schizophrenia. Schizophrenia Research, 1991, 6, 31-39.	2.0	17
141	Hereditary intermediate phenotypes in African American hypertension. Ethnicity and Health, 1996, 1, 117-128.	2.5	17
142	Factitious pheochromocytoma: Novel mimickry by valsalva maneuver and clues to diagnosis*. American Journal of Hypertension, 1995, 8, 651-655.	2.0	16
143	The angiotensin II receptor (Agtr1a): functional regulatory polymorphisms in a locus genetically linked to blood pressure variation in the mouse. Physiological Genomics, 2003, 14, 83-93.	2.3	16
144	Human Tyrosine Hydroxylase Natural Allelic Variation: Influence on Autonomic Function and Hypertension. Cellular and Molecular Neurobiology, 2010, 30, 1391-1394.	3.3	16

#	Article	IF	Citations
145	Reprint of: Catestatin: A multifunctional peptide from chromogranin A. Regulatory Peptides, 2010, 165, 52-62.	1.9	16
146	Global metabolic consequences of the chromogranin A-null model of hypertension: transcriptomic detection, pathway identification, and experimental verification. Physiological Genomics, 2010, 40, 195-207.	2.3	16
147	Catecholamine Storage Vesicles: Role of Core Protein Genetic Polymorphisms in Hypertension. Current Hypertension Reports, 2011, 13, 36-45.	3.5	16
148	Reduced renovascular resistance by clonidine. Clinical Pharmacology and Therapeutics, 1979, 26, 572-577.	4.7	15
149	A Novel, Catecholamine Release-Inhibitory Peptide from Chromogranin A: Autocrine Control of Nicotinic Cholinergic-Stimulated Exocytosis. Advances in Pharmacology, 1997, 42, 260-264.	2.0	15
150	Chromogranin B: intraâ€•and extraâ€cellular mechanisms to regulate catecholamine storage and release, in catecholaminergic cells and organisms. Journal of Neurochemistry, 2014, 129, 48-59.	3.9	15
151	Recirculation: A Uremic Syndrome Complicating the use of Prosthetic Arteriovenous Fistulas for Hemodialysis. Journal of Dialysis, 1978, 2, 251-259.	0.4	14
152	Progression of Chronic Kidney Disease: Adrenergic Genetic Influence on Glomerular Filtration Rate Decline in Hypertensive Nephrosclerosis. American Journal of Nephrology, 2010, 32, 23-30.	3.1	14
153	Common Charge-Shift Mutation Glu65Lys in K+ Channel Î²1-Subunit KCNMB1: Pleiotropic Consequences for Glomerular Filtration Rate and Progressive Renal Disease. American Journal of Nephrology, 2010, 32, 414-424.	3.1	14
154	Polymorphisms at the F12 and KLKB1 loci have significant trait association with activation of the renin-angiotensin system. BMC Medical Genetics, 2016, 17, 21.	2.1	14
155	Neuroendocrine-Specific and Gastrin-Dependent Expression of a Chromogranin A-Luciferase Fusion Gene in Transgenic Mice. Gastroenterology, 2001, 121, 43-55.	1.3	13
156	Dopamine D1 receptor (DRD1) genetic polymorphism: pleiotropic effects on heritable renal traits. Kidney International, 2009, 76, 1070-1080.	5.2	13
157	Genes and environment. Journal of Hypertension, 2012, 30, 1961-1969.	0.5	13
158	Development of a pharmacophore model for the catecholamine release-inhibitory peptide catestatin: Virtual screening and functional testing identify novel small molecule therapeutics of hypertension. Bioorganic and Medicinal Chemistry, 2013, 21, 5855-5869.	3.0	13
159	Molecular Mechanism for Hypertensive Renal Disease. Journal of the American Society of Nephrology: JASN, 2015, 26, 1816-1825.	6.1	13
160	Identification of novel loci affecting circulating chromogranins and related peptides. Human Molecular Genetics, 2016, 26, ddw380.	2.9	13
161	Neuroendocrine Cell Typeâ€Specific and Inducible Expression of Chromogranin/Secretogranin Genes. Annals of the New York Academy of Sciences, 2002, 971, 27-38.	3.8	12
162	Granulogenesis in Non-neuroendocrine COS-7 Cells Induced by EGFP-tagged Chromogranin A Gene Transfection: Identical and Distinct Distribution of CgA and EGFP. Journal of Histochemistry and Cytochemistry, 2007, 55, 487-493.	2.5	12

#	Article	IF	Citations
163	Long human CHGA flanking chromosome 14 sequence required for optimal BAC transgenic â€œrescueâ€•of disease phenotypes in the mouse Chga knockout. Physiological Genomics, 2010, 41, 91-101.	2.3	12
164	Isoprostane, an â€œIntermediate Phenotypeâ€•for Oxidative Stress. Journal of the American College of Cardiology, 2010, 56, 1338-1350.	2.8	12
165	Heritable Influence of DBH on Adrenergic and Renal Function: Twin and Disease Studies. PLoS ONE, 2013, 8, e82956.	2.5	12
166	Clinical improvement in parkinsonian patients undergoing adrenal to caudate transplantation is not reflected by chromogranin a or basic fibroblast growth factor in ventricular fluid. Experimental Neurology, 1991, 111, 276-281.	4.1	11
167	The Catecholamine Releaseâ€•Inhibitory â€œCatestatinâ€•Region of Chromogranin A. Annals of the New York Academy of Sciences, 2002, 971, 533-535.	3.8	11
168	Genome-wide linkage analysis of chromogranin B expression in the CEPH pedigrees: implications for exocytotic sympathochromaffin secretion in humans. Physiological Genomics, 2004, 18, 119-127.	2.3	11
169	Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis. Nephrology Dialysis Transplantation, 2009, 24, 3677-3686.	0.7	11
170	The Protein Architecture of Human Secretory Vesicles Reveals Differential Regulation of Signaling Molecule Secretion by Protein Kinases. PLoS ONE, 2012, 7, e41134.	2.5	11
171	Human Heart Rate. Journal of the American College of Cardiology, 2014, 63, 358-368.	2.8	11
172	Pharmacogenomics of hypertension. Current Opinion in Nephrology and Hypertension, 2003, 12, 61-70.	2.0	11
173	CSF chromogranin A-like immunoreactivity in schizophrenia: Relationships with REM latency and slow wave sleep. Psychiatry Research, 1992, 42, 53-63.	3.3	10
174	Urocortin 2 Lowers Blood Pressure and Reduces Plasma Catecholamine Levels in Mice with Hyperadrenergic Activity. Endocrinology, 2010, 151, 4820-4829.	2.8	10
175	Systematic polymorphism discovery after genome-wide identification of potential susceptibility loci in a hereditary rodent model of human hypertension. Blood Pressure, 2011, 20, 222-231.	1.5	10
176	Naturally Occurring Genetic Variants in Human Chromogranin A (CHGA) Associated with Hypertension as well as Hypertensive Renal Disease. Cellular and Molecular Neurobiology, 2010, 30, 1395-1400.	3.3	9
177	Contemporary approaches to genetic influences on hypertension. Current Opinion in Nephrology and Hypertension, 2011, 20, 23-30.	2.0	9
178	Natural Variation within the Neuronal Nicotinic Acetylcholine Receptor Cluster on Human Chromosome 15q24: Influence on Heritable Autonomic Traits in Twin Pairs. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 419-428.	2.5	8
179	Heredity and cardiometabolic risk. Journal of Hypertension, 2013, 31, 123-133.	0.5	8
180	Chromaffin Cell Catecholamine Secretion: Bisindolylmaleimide Compounds Exhibit Novel and Potent Antagonist Effects at the Nicotinic Cholinergic Receptor in Pheochromocytoma Cells. Molecular Pharmacology, 2002, 61, 1340-1347.	2.3	7

#	Article	IF	Citations
181	Intracellular Protein Trafficking into Catecholamine Storage Vesicles. Annals of the New York Academy of Sciences, 2002, 971, 262-265.	3.8	7
182	Granins and Catecholamines. Advances in Pharmacology, 2013, 68, 93-113.	2.0	7
183	Cox-2 Promotes Chromogranin A Expression and Bioactivity: Evidence for a Prostaglandin E2-Dependent Mechanism and the Involvement of a Proximal Cyclic Adenosine 5â€²-Monophosphate-Responsive Element. Endocrinology, 2007, 148, 4310-4317.	2.8	6
184	Conserved regulatory motifs at phenylethanolamine N-methyltransferase (PNMT) are disrupted by common functional genetic variation: an integrated computational/experimental approach. Mammalian Genome, 2010, 21, 195-204.	2.2	6
185	Genetic Variation Within a Metabolic Motif in the Chromogranin A Promoter: Pleiotropic Influence on Cardiometabolic Risk Traits in Twins. American Journal of Hypertension, 2012, 25, 29-40.	2.0	6
186	Integrated Computational and Experimental Analysis of the Neuroendocrine Transcriptome in Genetic Hypertension Identifies Novel Control Points for the Cardiometabolic Syndrome. Circulation: Cardiovascular Genetics, 2012, 5, 430-440.	5.1	6
187	A new common functional coding variant at the DDC gene change renal enzyme activity and modify renal dopamine function. Scientific Reports, 2019, 9, 5055.	3.3	6
188	Association of Functional Kallikrein-1 Promoter Polymorphisms and Acute Kidney Injury: A Case-Control and Longitudinal Cohort Study. Nephron Clinical Practice, 2013, 122, 107-113.	2.3	5
189	Catecholamine biosynthesis and secretion: physiological and pharmacological effects of secretin. Cell and Tissue Research, 2011, 345, 87-102.	2.9	4
190	Chromogranin A pathway: from pathogenic molecule to renal disease. Journal of Hypertension, 2020, 38, 456-466.	0.5	3
191	Hereditary dysautonomias: current knowledge and collaborations for the future. Clinical Autonomic Research, 2003, 13, 180-195.	2.5	2
192	Proteomic Analysis Yields an Unexpected Trans -Acting Point in Control of the Human Sympathochromaffin Phenotype. Circulation: Cardiovascular Genetics, 2011, 4, 437-445.	5.1	2
193	Genetic variation at the deltaâ€sarcoglycan (<scp>SGCD</scp>) locus elevates heritable sympathetic nerve activity in human twin pairs. Journal of Neurochemistry, 2013, 127, 750-761.	3.9	2
194	Complex Renal Traits: Role of Adrenergic Genetic Polymorphism. Journal of the American Society of Nephrology: JASN, 2009, 20, 1172-1174.	6.1	1
195	Catecholamines, Pheochromocytoma, and Hypertension: Genomic Insights. , 2007, , 895-911.		0
196	Hypertension as a Maladaptive "Fight-or-Flight" Response?: Confirmatory Molecular Genetic Evidence From the Human Catecholamine Biosynthetic Pathway. American Journal of Hypertension, 2010, 23, 1250-1251.	2.0	0
197	Polymorphisms of Î± 1a and Î± 1b â€adrenergic receptors help identify patients with arterial hypertension. FASEB Journal, 2007, 21, A422.	0.5	0